|View printer-friendly version|
An audio replay of the webcast will be available until 11:59 p.m. ET/ 8:59 p.m. PT on April 9, 2010. Access numbers for the replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international), and the passcode is 15744931.
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, Pfizer Inc., and Daiichi-Sankyo. For more information, please visit the company's web site at http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.exelixis.com&esheet=6198914&lan=en_US&anchor=http%3A%2F%2Fwww.exelixis.com&index=2&md5=b66a3d335ba53c25d12efba4179ad449.
Exelixis and the Exelixis logo are registered U.S. trademarks.
SOURCE: Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
DeDe Sheel, 650-837-8231
Associate Director, Investor Relations